(3R)-3-methyl-4-(1-methyl-7-(1-methyl-1H-pyrazol-5-yl)-3-(1H-pyrazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)morpholine

ID: ALA5173530

Chembl Id: CHEMBL5173530

PubChem CID: 156404392

Max Phase: Preclinical

Molecular Formula: C18H21N9O

Molecular Weight: 379.43

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@@H]1COCCN1c1nc(-c2ccnn2C)c2c(n1)c(-c1ccn[nH]1)nn2C

Standard InChI:  InChI=1S/C18H21N9O/c1-11-10-28-9-8-27(11)18-21-15(13-5-7-20-25(13)2)17-16(22-18)14(24-26(17)3)12-4-6-19-23-12/h4-7,11H,8-10H2,1-3H3,(H,19,23)/t11-/m1/s1

Standard InChI Key:  AIRFZNQGDRBDOC-LLVKDONJSA-N

Alternative Forms

  1. Parent:

    ALA5173530

    ---

Associated Targets(Human)

ATR Tchem ATR/ATRIP (56 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LoVo (4724 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 379.43Molecular Weight (Monoisotopic): 379.1869AlogP: 1.38#Rotatable Bonds: 3
Polar Surface Area: 102.57Molecular Species: NEUTRALHBA: 9HBD: 1
#RO5 Violations: HBA (Lipinski): 10HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 9.98CX Basic pKa: 2.02CX LogP: 1.51CX LogD: 1.50
Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.57Np Likeness Score: -1.57

References

1. Cheng B, Pan W, Xing Y, Xiao Y, Chen J, Xu Z..  (2022)  Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.,  230  [PMID:35051747] [10.1016/j.ejmech.2022.114109]

Source